桃花汤治疗溃疡性结肠炎疗效的系统评价

Systematic review of therapeutic effect of taohua decoction on ulcerative colitis

目的评价桃花汤治疗溃疡性结肠炎的临床疗效。方法检索中国知网、万方数据知识服务平台、维普网、中国生物医学数据库、PubMed、Web of science、Cochrane library,筛选文献并采集文献相关信息,使用Review Manager 5.3评价偏倚风险并对各疗效指标进行系统评价。结果检索获得546篇文献,经过剔重和筛选最终纳入16篇文献。Meta分析显示临床总有效率:RR=1.19,95%CI:1.14~1.24,P<0.001,结肠镜积分:MD=-0.61,95%CI:-1.11~-0.11,P=0.020,肿瘤坏死因子-α:MD=-22.18,95%CI:-36.70~-7.66,P=0.003,C反应蛋白:MD=-10.85,95%CI:-30.48~8.77,P=0.280,不良反应发生率:RR=0.40,95%CI:0.24~0.65,P<0.001。结论桃花汤治疗溃疡性结肠炎在临床总有效率、结肠镜积分、肿瘤坏死因子-α及不良反应发生率方面优于对照组。

Objective To evaluate the clinical efficacy of Taohua Decoction in treating ulcerative colitis.Methods Searching CNKI,Wanfang,Weipu,China Biomedical Database,PubMed,Web of science,and Cochrane library,Screening literature and collecting literature related information.Using Review Manager 5.3 to evaluate the risk of bias and systematically evaluate efficacy indicators.Results A total of 546 articles were retrieved,and 16 were eventually included after censoring and screening.Meta analysis showed that total clinical effective rate:RR=1.19,95%CI:1.14–1.24,P<0.001.Colonoscopy score:MD=-0.61,95%CI:-1.11–-0.11,P=0.02.Tumor necrosis factor(TNF)-α:MD=-22.18,95%CI:-36.70–-7.66,P=0.003.C-reactive protein:MD=-10.85,95%CI:-30.48–8.77,P=0.28.Incidence of adverse reactions:RR=0.40,95%CI:0.24–0.65,P<0.001.Conclusion The total clinical effective rate,colonoscopy score,TNF-αand incidence of adverse reactions of Taohua Decoction in treating ulcerative colitis was superior to that in the control group.There was no significant difference between Taohua Decoction and the control group in reducing C-reactive protein.